Usefulness of contrast-enhanced ultrasonography to evaluate the post-treatment responses of radiofrequency ablation for hepatocellular carcinoma: Comparison with dynamic CT

Oncology (Switzerland)

Volumn 84, Issue , 2013, Pages 51-57

  Inoue, Tatsuo ^a   Kudo, Masatoshi ^a   Hatanaka, Kinuyo ^a   Arizumi, Tadaaki ^a   Takita, Masahiro ^a   Kitai, Satoshi ^a   Yada, Norihisa ^a   Hagiwara, Satoru ^a   Minami, Yasunori ^a   Sakurai, Toshiharu ^a   Ueshima, Kazuomi ^a   Nishida, Naoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Contrast enhanced ultrasonography; Defect reperfusion imaging; Hepatocellular carcinoma; Radiofrequency ablation; Treatment response

Indexed keywords

PERFLUBUTANE;

ADULT; AGED; CANCER RECURRENCE; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTRAST ENHANCED ULTRASONOGRAPHY; DYNAMIC COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENCE RISK; TREATMENT RESPONSE;

EID: 84874348168     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000345890     Document Type: Conference Paper

References (31)

1. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al: Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012; 107: 569-578.
2. Shibata T, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K, et al: Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 2002; 223: 331-337.
3. Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ: Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000; 7: 593-600.
4. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS: Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210: 655-661.
5. Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, et al: Percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1, 000 cases. Cancer 2005; 103: 1201-1209.
6. Teratani T, Yoshida H, Shiina S, Obi S, Sato S, Tateishi R, et al: Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology 2006; 43: 1101-1108.
7. Camma C, Di Marco V, Orlando A, Sandonato L, Casaril A, Parisi P, et al: Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. J Hepatol 2005; 42: 535-540.
8. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al: Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-240.
9. Tiong L, Maddern GJ: Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg 2011; 98: 1210-1224.
10. Lim HK, Choi D, Lee WJ, Kim SH, Lee SJ, Jang HJ, et al: Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology 2001; 221: 447-454.
11. Chopra S, Dodd GD 3rd, Chintapalli KN, Leyendecker JR, Karahan OI, Rhim H: Tumor recurrence after radiofrequency thermal ablation of hepatic tumors: spectrum of findings on dual-phase contrast-enhanced CT. AJR Am J Roentgenol 2001; 177: 381-387.
12. Lee JM, Yoon JH, Joo I, Woo HS: Rencet advances in CT and MR imaging for evaluation of hepatocellular carcinoma. Liver Cancer 2012; 1: 22-40.
13. Halpern EJ, McCue PA, Aksnes AK, Hagen EK, Frauscher F, Gomella LG: Contrast-enhanced US of the prostate with Sonazoid: comparison with whole-mount prostatectomy specimens in 12 patients. Radiology 2002; 222: 361-366.
14. Kudo M, Hatanaka K, Kumada T, Toyoda H, Tada T: Double-contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma. Am J Gastroenterol 2011; 106: 368-370.
15. Hatanaka K, Kudo M, Minami Y, Maekawa K: Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology 2008; 75(suppl 1):42-47.
16. Kudo M, Hatanaka K, Maekawa K: Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using sonazoid in the management of hepatocellular carcinoma. Oncology 2010; 78(suppl 1): 40-45.
17. Kudo M, Okanoue T, Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007; 72(suppl 1):2-15.
18. Bruix J, Sherman M: Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
19. Kudo M, Hatanaka K, Maekawa K: Defect reperfusion imaging, a newly developed novel technology using Sonazoid in the treatment of hepatocellular carcinoma. J Med Ultrasound 2008; 16: 169-175.
20. Bartolozzi C, Lencioni R, Ricci P, Paolicchi A, Rossi P, Passariello R: Hepatocellular carcinoma treatment with percutaneous ethanol injection: evaluation with contrast-enhanced color Doppler US. Radiology 1998; 209: 387-393.
21. Ding H, Kudo M, Onda H, Suetomi Y, Minami Y, Chung H, et al: Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phaseinversion harmonic US: comparison with dynamic CT. Radiology 2001; 221: 721-730.
22. Ding H, Kudo M, Onda H, Suetomi Y, Minami Y, Maekawa K: Contrast-enhanced subtraction harmonic sonography for evaluating treatment response in patients with hepatocellular carcinoma. AJR Am J Roentgenol 2001; 176: 661-666.
23. Frieser M, Kiesel J, Lindner A, Bernatik T, Haensler JM, Janka R, et al: Efficacy of contrast-enhanced US versus CT or MRI for the therapeutic control of percutaneous radiofrequency ablation in the case of hepatic malignancies. Ultraschall Med 2011; 32: 148-153.
24. Ricci P, Cantisani V, Drudi F, Pagliara E, Bezzi M, Meloni F, et al: Is contrast-enhanced US alternative to spiral CT in the assessment of treatment outcome of radiofrequency ablation in hepatocellular carcinoma? Ultraschall Med 2009; 30: 252-258.
25. Kim YS, Rhim H, Cho OK, Koh BH, Kim Y: Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors. Eur J Radiol 2006; 59: 432-441.
26. Nakazawa T, Kokubu S, Shibuya A, Ono K, Watanabe M, Hidaka H, et al: Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol 2007; 188: 480-448.
27. Tokunaga S, Koda M, Matono T, Sugihara T, Nagahara T, Ueki M, et al: Assessment of ablative margin by MRI with ferucarbotran in radiofrequency ablation for liver cancer: comparison with enhanced CT. Br J Radiol 2012; 85: 745-752.
28. Koda M, Tokunaga S, Miyoshi K, Kishina M, Fujise Y, Kato J, et al: Assessment of ablative margin by unenhanced magnetic resonance imaging after radiofrequency ablation for hepatocellular carcinoma. Eur J Radiol 2012; 81: 2730-2736.
29. Grobner T, Prischl FC: Gadolinium and nephrogenic systemic fibrosis. Kidney Int 2007; 72: 260-264.
30. Joo I, Choi BI: New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer 2012; 1: 94-109.
31. Salvatore V, Bolondi L: Clinical impact of ultrasound-related techniques in the diagnosis of focal liver lesions. Liver Cancer, 2012; 1: 238-246.